Compare F5 Inc (FFIV) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Inovio Pharmaceuticals Inc — how do they compare? F5 Inc trades at $475.86 (market cap $26.14B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: F5 Inc is far larger — about 233× Inovio Pharmaceuticals Inc's market cap, and F5 Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FFIV | INO | |
|---|---|---|
Market Cap | $26.14B | $112.19M |
Volume | 503,146 | 3,201,278 |
Sector | Technology | Health |
52-Week High | $469.79 | $2.65 |
52-Week Low | $223.99 | $0.66 |
Typical Hold Time | 38 Days | 43 Days |
Enterprise Value | $24.78B | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FFIV trades at $467.57, up 0.2% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.73 beating expectations of $4.00. Revenue grew to $3.09B in 2025, and net income margin improved to 21.95%. Recent news highlights F5's leadership in WAAP platforms and AI security partnerships, reinforcing its market position.
The outlook remains positive given earnings momentum and strategic initiatives in AI security, though valuation multiples like P/E of 36.78 suggest premium pricing. Risks include competitive pressures and execution challenges in integrating new technologies. Analyst consensus is mixed with a $416.60 price target below current levels, indicating caution despite growth prospects.
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
